Cheplapharm Arzneimittel GmbH
http://www.cheplapharm.com/1/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cheplapharm Arzneimittel GmbH
Deal Watch: Merck KGaA Enhances Cell/Gene Therapy Capabilities With Mirus Takeout
Plus deals involving Immunis/Toray, AstraZeneca/Nona, Swixx/Biopas, Deimos/G1, Serum Institute of India/IntegriMedical/ImmunityBio plus tech transfer agreements and deals in brief.
Asia Deal Watch: SciClone Obtains Commercial Rights In China To Menarini Breast Cancer Drug
Plus deals involving Fujimoto/Egetis, Chugai/Cheplapharm, Celest/Senti, Shionogi/Apnimed, Jiangsu Hengrui/Merck KGaA, Jiangsu Hengrui/Elevar, Sun/Zydus, C4U/Healiva, Shanghai Henlius/Intas, Ono/Turbine, EpimAB/Almirall and Alar/Indivior.
Lilly Sees Massive Growth For Mounjaro Ahead Of Obesity Approval
With more paid prescriptions adding to Mounjaro revenue, along with increasing prescription volume, Lilly is working to increase supply of the GLP-1/GIP agonist as it awaits FDA’s call on a weight-loss indication.
AZ Sells EU Rights To Former Jewel In The Crown, Crestor
The cholesterol lowerer Crestor, which had peak sales of over $6.60bn, helped AstraZeneca reinvigorate a flagging pipeline. Now it is deemed surplus to requirements.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Nutraceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice